Evolus Inc

Drug Manufacturers-Specialty & Generic

Prices are adjusted according to historical splits.

Evolus Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$472.17 million
Book Value:
Revenue TTM:
$148.62 million
Operating Margin TTM:
Gross Profit TTM:
$92.73 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Evolus Inc had its IPO on 2018-02-08 under the ticker symbol EOLS.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Evolus Inc has a staff strength of 215 employees.

Stock update

Shares of Evolus Inc opened at $8.46 at the start of the last trading session i.e. 2023-03-19.

The stocks traded within a range of $8.28 - $8.67, and closed at $8.37.

This is a -1.41% slip from the previous day's closing price.

A total volume of 606,200 shares were traded at the close of the day’s session.

In the last one week, shares of Evolus Inc have slipped by -2.45%.

Evolus Inc's Key Ratios

Evolus Inc has a market cap of $472.17 million, indicating a price to book ratio of 14.6487 and a price to sales ratio of 2.9729.

In the last 12-months Evolus Inc’s revenue was $148.62 million with a gross profit of $92.73 million and an EBITDA of $-53853000. The EBITDA ratio measures Evolus Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Evolus Inc’s operating margin was -38.74% while its return on assets stood at -16.53% with a return of equity of -148.27%.

In Q4, Evolus Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 25.9%.

Evolus Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.32 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Evolus Inc’s profitability.

Evolus Inc stock is trading at a EV to sales ratio of 3.1296 and a EV to EBITDA ratio of -6.3881. Its price to sales ratio in the trailing 12-months stood at 2.9729.

Evolus Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
Total Liabilities
Operating Cash Flow
Capital Expenditure
$2.29 million
Dividend Payout Ratio

Evolus Inc ended 2023 with $177983.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $177983.00 while shareholder equity stood at $18499.00.

Evolus Inc ended 2023 with $0 in deferred long-term liabilities, $46509.00 in other current liabilities, 1.00 in common stock, $-497294.00 in retained earnings and $21208.00 in goodwill. Its cash balance stood at $53922.00 and cash and short-term investments were $53922.00. The company’s total short-term debt was $1,320 while long-term debt stood at $71.88 million.

Evolus Inc’s total current assets stands at $100802.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $22448.00 compared to accounts payable of $33729.00 and inventory worth $18852.00.

In 2023, Evolus Inc's operating cash flow was $-1391000.00 while its capital expenditure stood at $2.29 million.

Comparatively, Evolus Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Evolus Inc stock is currently trading at $8.37 per share. It touched a 52-week high of $14.34 and a 52-week low of $14.34. Analysts tracking the stock have a 12-month average target price of $16.56.

Its 50-day moving average was $9.22 and 200-day moving average was $9.49 The short ratio stood at 3.16 indicating a short percent outstanding of 0%.

Around 2420.1% of the company’s stock are held by insiders while 5817% are held by institutions.

Frequently Asked Questions About Evolus Inc

The stock symbol (also called stock or share ticker) of Evolus Inc is EOLS

The IPO of Evolus Inc took place on 2018-02-08

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Stevia Corp (STEV)
111 Inc (YI)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price


Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It serves self-pay aesthetic healthcare market. Evolus, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.


520 Newport Center Drive, Newport Beach, CA, United States, 92660